Meiji Yasuda Asset Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$3.98M |
| 2 |
Amazon
AMZN
|
+$3.04M |
| 3 |
Tesla
TSLA
|
+$2.66M |
| 4 |
Union Pacific
UNP
|
+$2.66M |
| 5 |
Apple
AAPL
|
+$2.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.38M |
| 2 |
Colgate-Palmolive
CL
|
+$2.12M |
| 3 |
Medtronic
MDT
|
+$1.61M |
| 4 |
Moderna
MRNA
|
+$1.56M |
| 5 |
Generac Holdings
GNRC
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.83% |
| 2 | Healthcare | 15.39% |
| 3 | Financials | 11.91% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 9.21% |
Similar funds
Meiji Yasuda Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Meiji Yasuda Asset Management held 546 positions worth $1.62B, up 15% from $1.41B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Meiji Yasuda Asset Management deployed $56.5M of net new capital in Q4 2021, opening 32 new positions and adding to 378 existing holdings. Its largest new stake was Neurocrine Biosciences: 6,430 shares worth $548K.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $2.38M trimmed.
- Meiji Yasuda Asset Management's largest Q4 2021 buy was Neurocrine Biosciences: 6,430 shares worth $548K.
- Meiji Yasuda Asset Management added most to Comcast in Q4 2021, an estimated $3.98M increase.
- Meiji Yasuda Asset Management's biggest Q4 2021 reduction was Eli Lilly, cutting an estimated $2.38M.
- Meiji Yasuda Asset Management fully exited News Corp Class A in Q4 2021, selling an estimated $1.2M.
- Meiji Yasuda Asset Management's ten largest holdings make up 23% of its $1.62B portfolio in Q4 2021.
- Meiji Yasuda Asset Management opened 32 new positions and closed 11 in Q4 2021.
- Meiji Yasuda Asset Management's portfolio value rose 15% quarter-over-quarter to $1.62B.
Based on Meiji Yasuda Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.